Transaction details
Nicole Murphy, who serves as Head of Pharmaceutical Operations and Technology at Biogen, acquired 3 shares of the company’s common stock on February 12, 2026. The shares were bought at $195.035 each, bringing the total cost of the purchase to $585. The transaction was disclosed in a Form 4 filing with the Securities and Exchange Commission.
Post-transaction holdings
Following the purchase, the filing indicates Murphy directly holds 19,611.0408 shares of Biogen. At prevailing market prices, that stake is valued at roughly $3.8 million in the company, which has a market capitalization cited at $28.7 billion.
Equity grants and vesting
In addition to the open-market purchase, Murphy was granted 10,560 Restricted Stock Units on February 13, 2026. Those RSUs are structured to vest in three equal annual installments, with the first vesting date set for February 13, 2027. The RSUs carry an expiration date of February 13, 2029.
Share price context
Biogen shares have shown notable momentum recently, trading near a 52-week high of $202.41 and rising 43.9% over the past six months. Separately, an analysis referenced in the filing materials characterizes Biogen as appearing undervalued and assigns a "GREAT" financial health score.
Analyst views and price targets
Analysts continue to express a generally positive stance on the stock. Consensus remains a moderate buy, with individual price targets spanning from $143 to $260. Several firms adjusted their targets after the company reported a stronger-than-expected quarter: TD Cowen raised its target to $215, RBC Capital increased its target to $233, and BMO Capital set a target of $196. Goldman Sachs reiterated its Buy rating, pointing to Leqembi revenue that exceeded its estimates.
Quarterly performance
Biogen’s fourth-quarter results, as reported to analysts, outperformed consensus: revenue beat estimates by 3% and earnings per share exceeded forecasts by 17%, according to Bernstein. Those results prompted multiple firms to revisit their projections and price targets for the company.
Bottom line
The insider purchase by Murphy was modest in dollar terms but accompanies a broader backdrop of stronger-than-expected quarterly results and multiple analysts raising targets. Murphy’s additional RSU grant and the wide range of analyst price targets highlight both confidence among some market participants and differing valuations within the analyst community.